本帖最后由 老马 于 2012-1-13 21:20 编辑 ; T+ a9 ^2 [+ z% w u/ K
* d$ d9 _& `7 u8 ?- E) \
爱必妥和阿瓦斯丁的比较
- v( m- c y( Q/ w& K
& K% N' p* I( o) R8 i* M
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/0 ?1 W8 v. O0 `
o( `. }! F+ s. H
/ i- W: J& g2 ~, |$ U8 j
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/7 t+ u7 k, r, j( f" B* E+ z
==================================================
: {3 G# V) N4 }Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)# v6 G$ e" \& J7 _7 G! r
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.2 e" r7 r; u4 [. g$ s1 u `
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
' m3 e' J" O I; O3 p
|
显身卡
# R+ M* u4 ]" H* w5 m; p3 i) l
